T H17 cytokines in autoimmune neuro-inflammation

Current Opinion in Immunology

Volumn 23, Issue 6, 2011, Pages 707-712

  Becher, Burkhard ^a   Segal, Benjamin M ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FINGOLIMOD; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; MYELIN; NEUTRALIZING ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CELL POLARITY; CYTOKINE RELEASE; DEMYELINATING DISEASE; DEMYELINATION; HUMAN; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; REVIEW; TH1 CELL; TH17 CELL;

ANIMALS; BIOLOGICAL MARKERS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INFLAMMATION; INTERLEUKINS; TH17 CELLS;

EID: 82955228112     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.08.005     Document Type: Review

References (62)

1. O'Garra A., Steinman L., Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 1997, 9:872-883.
2. Fouser L.A., Wright J.F., Dunussi-Joannopoulos K., Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 2008, 226:87-102.
3. Littman D.R., Rudensky A.Y. Th17 regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
4. Ruuls S.R., Sedgwick J.D. Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis. Immunol Cell Biol 1998, 76:65-73.
5. Willenborg D.O., Fordham S., Bernard C.C., Cowden W.B., Ramshaw I.A. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996, 157:3223-3227.
6. Lees J.R., Golumbek P.T., Sim J., Dorsey D., Russell J.H. Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J Exp Med 2008, 205:2633-2642.
7. Gutcher I., Urich E., Wolter K., Prinz M., Becher B. Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. Nat Immunol 2006, 7:946-953.
8. Liblau R., Steinman L., Brocke S. Experimental autoimmune encephalomyelitis in IL-4-deficient mice. Int Immunol 1997, 9:799-803.
9. Segal B.M., Dwyer B.K., Shevach E.M. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998, 187:537-546.
10. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002, 110:493-497.
11. Gran B., Zhang G.X., Yu S., Li J., Chen X.H., Ventura E.S., Kamoun M., Rostami A. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002, 169:7104-7110.
12. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Vega F., Yu N., Wang J., Singh K., et al. Novel p19 protein engages IL-12p40 to form a cytokine IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
13. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
14. Gutcher I., Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007, 117:1119-1127.
15. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
16. Kroenke M.A., Carlson T.J., Andjelkovic A.V., Segal B.M. IL-12- IL-23-modulated T cells induce distinct types of EAE based on histology CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008.
17. Kroenke M.A., Segal B.M. IL-23 modulated myelin-specific T cells induce EAE via an IFNgamma driven IL-17 independent pathway. Brain Behav Immun 2011, 25:932-937.
18. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y: IL-17 Plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:566-573.
19. Hofstetter H.H., Ibrahim S.M., Koczan D., Kruse N., Weishaupt A., Toyka K.V., Gold R. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005, 237:123-130.
20. Haak S., Croxford A.L., Kreymborg K., Heppner F.L., Pouly S., Becher B., Waisman A. IL-17A andIL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009, 119:61-69.
21. Kreymborg K., Etzensperger R., Dumoutier L., Haak S., Rebollo A., Buch T., Heppner F.L., Renauld J.C., Becher B. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007, 179:8098-8104.
22. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., Schluns K., Tian Q., Watowich S.S., Jetten A.M., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
23. Coquet J.M., Chakravarti S., Smyth M.J., Godfrey D.I. Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol 2008, 180:7097-7101.
24. Sonderegger I., Kisielow J., Meier R., King C., Kopf M. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo. Eur J Immunol 2008, 38:1833-1838.
25. Steinman L. A rush to judgment on Th17. J Exp Med 2008, 205:1517-1522.
26. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007, 13:1173-1175.
27. Carlson T., Kroenke M., Rao P., Lane T.E., Segal B. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med 2008, 205:811-823.
28. Kroenke M.A., Chensue S.W., Segal B.M. EAE mediated by a non-IFN-gamma/non-IL-17 pathway. Eur J Immunol 2010, 40:2340-2348.
29. Stromnes I.M., Cerretti L.M., Liggitt D., Harris R.A., Goverman J.M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008, 14:337-342.
30. McGeachy M.J., Cua D.J. Th17 cell differentiation: the long and winding road. Immunity 2008, 28:445-453.
31. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., Cua D.J. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
32. Gyulveszi G., Haak S., Becher B. IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo. Eur J Immunol 2009, 39:1864-1869.
33. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., Uccelli A., Lanzavecchia A., Engelhardt B., Sallusto F. C-C chemokine receptor 6-regulated entry of T(H)-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009, 10:514-523.
34. O'Connor R.A., Prendergast C.T., Sabatos C.A., Lau C.W., Leech M.D., Wraith D.C., Anderton S.M. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2008, 181:3750-3754.
35. El-Behi M., Ciric B., Dai H., Yan Y., Cullimore M., Safavi F., Zhang G.X., Dittel B.N., Rostami A. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 2011, 12:568-575.
36. Codarri L., Gyulveszi G., Tosevski V., Hesske L., Fontana A., Magnenat L., Suter T., Becher B. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011, 12:560-567.
37. McQualter J.L., Darwiche R., Ewing C., Onuki M., Kay T.W., Hamilton J.A., Reid H.H., Bernard C.C. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 2001, 194:873-882.
38. King I.L., Dickendesher T.L., Segal B.M. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009, 113:3190-3197.
39. Deshpande P., King I.L., Segal B.M. Cutting edge: CNS CD11c+ cells from mice with encephalomyelitis polarize Th17 cells and support CD25+CD4+ T cell-mediated immunosuppression, suggesting dual roles in the disease process. J Immunol 2007, 178:6695-6699.
40. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J., Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005, 11:328-334.
41. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005, 11:335-339.
42. King I.L., Kroenke M.A., Segal B.M. GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J Exp Med 2010, 207:953-961.
43. Lee Y.K., Turner H., Maynard C.L., Oliver J.R., Chen D., Elson C.O., Weaver C.T. Late developmental plasticity in the T helper 17 lineage. Immunity 2008, 30:92-107.
44. Annunziato F., Romagnani S. The transient nature of the Th17 phenotype. Eur J Immunol 2010, 40:3312-3316.
45. Hirota K., Duarte J.H., Veldhoen M., Hornsby E., Li Y., Cua D.J., Ahlfors H., Wilhelm C., Tolaini M., Menzel U., et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011, 12:255-263.
46. Bending D., De la Pena H., Veldhoen M., Phillips J.M., Uyttenhove C., Stockinger B., Cooke A. Highly purified Th17 cells from BDC2. 5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009, 119:565-572.
47. Kurschus F.C., Croxford A.L., Heinen A.P., Wortge S., Ielo D., Waisman A. Genetic proof for the transient nature of the Th17 phenotype. Eur J Immunol 2010, 40:3336-3346.
48. Kebir H., Ifergan I., Alvarez J.I., Bernard M., Poirier J., Arbour N., Duquette P., Prat A. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009, 66:390-402.
49. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999, 5:101-104.
50. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8:500-508.
51. Brucklacher-Waldert V., Stuerner K., Kolster M., Wolthausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
52. Durelli L., Conti L., Clerico M., Boselli D., Contessa G., Ripellino P., Ferrero B., Eid P., Novelli F. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009, 65:499-509.
53. Li Y., Wang H., Long Y., Lu Z., Hu X. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2011, 234:155-160.
54. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155.
55. Vaknin-Dembinsky A., Balashov K., Weiner H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006, 176:7768-7774.
56. Cohen J.A., Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011, 69:759-777.
57. Mehling M., Lindberg R., Raulf F., Kuhle J., Hess C., Kappos L., Brinkmann V. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010, 75:403-410.
58. Ramgolam V.S., Sha Y., Jin J., Zhang X., Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009, 183:5418-5427.
59. Sweeney C.M., Lonergan R., Basdeo S.A., Kinsella K., Dungan L.S., Higgins S.C., Kelly P.J., Costelloe L., Tubridy N., Mills K.H., et al. IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun 2011, 25:1170-1181.
60. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., Naves R., Han M., Zhong F., Castellanos J.G., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412.
61. Segal B.M., Constantinescu C.S., Raychaudhuri A., Kim L., Fidelus-Gort R., Kasper L.H. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008, 7:796-804.
62. Vollmer T.L., Wynn D.R., Alam M.S., Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler 2011, 17:181-191.